Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Norethisterone may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for 2. What you need to know before you take Norethisterone Tablets 3. How to take Norethisterone Tablets 4. Possible side effects 5. How to store Norethisterone Tablets
e Norethisterone Tablets Norethisterone Tablets may not be suitable for all women. Please read the following list carefully to see if any of these apply to you. Consult your doctor if you are not sure. Do not take Norethisterone Tablets:
may give you a pregnancy test altered when they are taken at the same time: before starting treatment or if
system attacks healthy tissues, Norethisterone Tablets typically causing symptoms such as painful joints and Always take this medicine exactly muscles, tiredness, fever and as your doctor has told you. rashes) Check with your doctor or
pg1/2 ART WORK CHECK BOX
Process Black
PRODUCT : CUSTOMER : FP CODE: PLANT LOCATION : DIMENSIONS : PHARMACODE No. : SAP CODE No. : TEXT FONT SIZE : FILE NAME : SOFTWARE : TYPEFACES : ARTWORK (DETAILS) RECEIVED ON : PROOF REVISION :
Norethisterone 5mg – 30 tablets Wockhardt UK FP2060 / FP4410 Daman (Kadiaya) (w)148 x (h)384mm 2853 228631 (PREVIOUS VERSION SAP CODE No. : 227510) 9 pt. Norethisterone 5mg_Leaflet_104373-9.ai Adobe Illustrator CS6 Myriad Pro Regular / Bold 30th September & 3rd October, 2024
R 1st PDF sent on – 3RD OCT. 2024 R 2nd PDF sent on – 7TH NOV. 2024 CHANGE CONTROL : Version changes due to change in: Size/Layout Regulatory Non-Regulatory Changes in detail: • Updated sections, 4.4 and 4.8,of SmPC/sections 1, 2, 3 and 4 of the PIL in line with the reference product
pg2/2
(32mm)
1st fold
(32mm)
2nd fold
(32mm)
3rd fold
(32mm)
4th fold
(32mm)
5th fold
(32mm)
6th fold
(32mm)
7th fold
(32mm)
8th fold
(32mm)
9th fold
(32mm)
10th fold
(32mm)
11th fold
(32mm)
becomes red and warm to search for MHRA Yellow Card in touch. the Google Play or Apple App If you get any of these symptoms, Store. you should stop taking the By reporting side effects you can tablets and see your doctor help provide more information immediately. on the safety of this medicine. Reasons for seeking medical advice during treatment It is important to see your doctor straightaway if you get:
weak or numb. If you get any side effects, talk to Symptoms of a deep-vein your doctor, pharmacist or nurse. thrombosis (DVT): This includes any possible side
12th fold
Taking Norethisterone Tablets for premenstrual tension – You will usually take one 5 mg tablet a day for 10 days, starting 16 days after your last period began. Taking Norethisterone Tablets for endometriosis – You will usually take 1 tablet 3 times (15 mg) a day for at least 6 months. If you have any irregular bleeding or spotting, your doctor may increase the dose to 4 or 5 tablets (20-25 mg) a day until this bleeding stops. Taking Norethisterone Tablets for breast cancer – You will usually take 8 tablets (40 mg) a day. Your doctor may increase this to 12 tablets (60 mg). Taking Norethisterone Tablets to delay your periods – You will usually take 1 tablet 3 times (15 mg) a day. You need to start taking the tablets 3 days before your period is due to start. Your period will usually start within 3 days of finishing the tablets. If you do not have a period after you finish a course of Norethisterone Tablets, check with your doctor in case you are pregnant. If you take more Norethisterone Tablets than you should If you take more Norethisterone Tablets than you should, contact your doctor straight away. If you forget to take Norethisterone Tablets Take the tablet as soon as you remember, and carry on taking the tablets at the normal times. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
You can also get the following Norethisterone Tablets side effects with medicines like Norethisterone Tablets: Keep this medicine out of the Effects on the reproductive sight and reach of children. system and breasts: bleeding
1. What Norethisterone Tablets are and what they are used for Norethisterone Tablets is one of a group of medicines called 'Progestogens'. Progestogens are similar to the natural female hormone progesterone. Norethisterone Tablets contains the progestogen called norethisterone as the active ingredient. Norethisterone Tablets has many uses. You can take Norethisterone Tablets to treat or manage:
Norethisterone 5mg Tablets comes as tablet containing 5mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Norethisterone 5mg Tablets is norethisterone.
This leaflet reproduces the patient information leaflet approved for Norethisterone 5mg Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
At low dose:
Dysfuntional uterine bleeding
Polymenorrhoea
Menorrhagia
Metropathia
Haemorrhagia
Pre-menstrual syndrome
Postponement of menstruation
At high dose:
Disseminated carcinoma of the breast.
Posology
Low dose
Dysfunctional uterine bleeding, polymenorrhoea, menorrhagia, dysmenorrhoea and metropathia haemorrhagia: 1 tablet three times daily for 10 days; bleeding usually stops within 48 hours. Withdrawal bleeding resembling true menstruation occurs a few days after the end of treatment. One tablet twice daily, from days 19 to 26 of the two subsequent cycles, should be given to prevent recurrence of the condition.
Endometriosis: 1 tablet three times daily for a minimum treatment period of six months. The dosage should be increased to 4 or 5 tablets a day if spotting occurs. The initial dosage should be resumed when bleeding or spotting stops.
Postponement of menstruation: 1 tablet three times daily, starting three days before the expected onset of menstruation. Menstruation usually follows within three days of finishing the treatment.
Pre-menstrual syndrome: 1 tablet daily from days 16 to 25 of the menstrual cycle.
High dose
For disseminated breast carcinoma the starting dose is 8 tablets (40mg) per day increasing to 12 tablets (60mg) if no regression is noted.
Method of administration
Oral Administration
Hypersensitivity to the active substance or any of the excipients listed in section 6.1
Pregnancy
Previous idiopathic or current venous thromboembolism (deep vein thrombosis, pulmonary embolism)
Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction)
Disturbance of liver function
History during pregnancy of idiopathic jaundice
Severe pruritus or pemphigoid gestationis
Undiagnosed irregular vaginal bleeding
Porphyria
If menstrual bleeding should fail to follow a course of Utovlan, the possibility of pregnancy must be excluded before a further course is given.
Therapy should be discontinued if the following occur:
- Jaundice or deterioration in liver function
- Significant increase in blood pressure
- New onset of migraine-type headache
Progestogens may cause fluid retention. Special care should be taken when prescribing norethisterone in patients with conditions which might be aggravated by this factor:
- Epilepsy
- Migraine
- Asthma
- Cardiac dysfunction
- Renal dysfunction
Risk of venous thromboembolism (VTE)
Long term use of low dose progestogens as part of combined oral contraception or combined hormone replacement therapy has been associated with an increased risk of venous thromboembolism, although the role of progestogens in this aetiology is uncertain. A patient who develops symptoms suggestive of thromboembolic complications should have her status and need for treatment carefully assessed before continuing therapy.
Any patient who develops an acute impairment of vision, proptosis, diplopia or migraine headache should be carefully evaluated ophthalmologically to exclude papilloedema or retinal vascular lesions before continuing medication.
Generally recognised risk factors for VTE include a personal history or family history, severe obesity (BMI >30 kg/m2) and systemic lupus erythematosus (SLE). There is no consensus about the possible role of varicose veins in VTE.
Treatment with steroid hormones may add to these risk factors. Personal or strong family history of thromboembolism or recurrent spontaneous abortion should be investigated in order to exclude a thrombophillic predisposition. Until a thorough evaluation of thrombophillic factors has been made or anticoagulant treatment initiated, use of progestogens in these patients should be viewed as contraindicated. Where a patient is already taking anticoagulants, the risks and benefits of progestogen therapy should be carefully considered.
The risk of VTE may be temporarily increased with prolonged immobilisation, major trauma or major surgery. As in all post-operative patients, scrupulous attention should be given to prophylactic measures to prevent VTE. Where prolonged immobilisation is likely to follow elective surgery, particularly abdominal or orthopaedic surgery to the lower limbs, consideration should be given to stopping progestogen therapy 4-6 weeks pre-operatively. Treatment should not be restarted until the patient is fully remobilised.
If VTE develops after initiating therapy the drug should be withdrawn. Patients should be advised to contact their doctor immediately if they become aware of a potential thromboembolic symptom (e.g., painful swelling in the leg, sudden pain in the chest, dyspnoea).
Hepatic adenoma - In very rare cases, hepatic adenomas may be associated with progesterone-only pill (POP) use. In some cases, the hepatic adenoma may decrease in size or become undetectable after discontinuation of norethisterone. Rupture of hepatic adenomas may cause death through intra-abdominal haemorrhage. In extremely rare cases, hepatocellular carcinoma may be associated with combined oral contraceptives use.
Interaction with other medicines
The metabolism of progestogens may be increased by concomitant administration of compounds known to induce drug-metabolising enzymes, specifically cytochrome P450 enzymes. These compounds include anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine) and anti-infectives (e.g., rifampicin, rifabutin, nevirapine, efavirenz, tetracyclines, ampicillin, oxacillin and cotrimoxazole)
Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones. Herbal preparations containing St John's wort (Hypericum perforatum) may induce the metabolism of progestogens. Progestogen levels may therefore be reduced.
Aminoglutethimide has been reported to decrease plasma levels of some progestogens.
Concurrent administration of cyclosporin and norethisterone has been reported to lead to increased plasma cyclosporin levels and/or decreased plasma norethisterone levels.
When used in combination with cytotoxic drugs, it is possible that progestogens may reduce the haematological toxicity of chemotherapy.
Special care should be taken when progestogens are administered with other drugs which also cause fluid retention, such as NSAIDs and vasodilators.
Other forms of interaction
Progestogens can influence certain laboratory tests (e.g., tests for hepatic function, thyroid function and coagulation).
Norethisterone is contraindicated in pregnancy
Norethisterone has no influence on the ability to drive and use machines.
Progestogens given alone at low doses have been associated with the following undesirable effects:
Genitourinary
breakthrough bleeding, spotting, amenorrhoea, abnormal uterine bleeding, (irregular, increase, decrease), alterations of cervical secretions, cervical erosions, prolonged anovulation
Breast
galactorrhoea, mastodynia, tenderness
Central Nervous System
depression, headache, dizziness, fatigue, insomnia, nervousness, somnolence, confusion, euphoria, loss of concentration, vision disorders
Gastrointestinal/Hepatobiliary
nausea, vomiting, cholestatic icterus/jaundice, constipation, diarrhoea, dry mouth, disturbed liver function
Neoplasms benign, malignant andunspecified (incl cysts and polyps)
hepatic adenoma
Metabolic & Nutritional
altered serum lipid and lipoprotein profiles, increased fasting glucose levels, increased fasting insulin levels, decreased glucose tolerance, adrenergic-like effects (e.g., fine hand tremors, sweating, cramps in calves at night), corticoid-like effects (e.g., Cushingoid syndrome), diabetic cataract, exacerbation of diabetes mellitus, glycosuria
Cardiovascular
thrombo-embolic disorders, cerebral and myocardial infarction, congestive heart failure, increased blood pressure, palpitations, pulmonary embolism, retinal thrombosis, tachycardia, thrombophlebitis
Skin & Mucous Membranes
acne, hirsutism, alopecia, pruritis, rash, urticaria
Allergy
hypersensitivity reactions (e.g., anaphylaxis & anaphylactoid reactions, angioedema)
Miscellaneous
oedema/fluid retention, bloating, weight gain, pyrexia, change in appetite, change in libido, hypercalcaemia, malaise
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Overdosage may be manifested by nausea, vomiting, breast enlargement and later vaginal bleeding. There is no specific antidote and treatment should be symptomatic.
Gastric lavage may be employed if the overdosage is large and the patient is seen sufficiently early (within four hours).
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Norethisterone 5mg Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.